Cefo Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 30, 2027The maintenance fee for Culture Vessel for Three-Dimensional Cell Cultivation and Three-Dimensional Cell Co-Cultivation Method Using Same (US 11,802,263) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
- 1 fee due Jun 3, 2027The maintenance fee for Method for inducing three-dimensional osteogenic differentiation of stem cells using hydrogel (US 10,494,601) comes due Jun 3, 2027. Unpaid by Dec 3, 2027, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,104,881 | Composition Comprising Plant-Derived Recombinant Human Serum Albumin, Lipids, and Plant Protein Hydrolysates as Active Ingredients for Cryopreservation of Stem Cells or Primary Cells In force · High confidence | In force | High confidence | |
| US 10,494,601 | Method for inducing three-dimensional osteogenic differentiation of stem cells using hydrogel In force · USPTO record | In force | USPTO record | |
| US 10,752,880 | Three-dimensional cell culture system and cell culture method using same In force · USPTO record | In force | USPTO record | |
| US 11,345,887 | Composition for Preserving Cells, Containing, as Active Ingredients, Plantderived Recombinant Human Serum Albumin and Plant Peptides In force · High confidence | In force | High confidence | |
| US 11,802,263 | Culture Vessel for Three-Dimensional Cell Cultivation and Three-Dimensional Cell Co-Cultivation Method Using Same In force · High confidence | In force | High confidence | |
| US 11,634,675 | Insertable Culture Container and Kit for Three-Dimensional Cell Culture, and Three-Dimensional Cell Co-Culture Method Using Same In force · High confidence | In force | High confidence | |
| US 12,702,130 | Cell Cryopreservation Device In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 1 abandoned · 1 no status recorded
Showing 1 to 3 of 3, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 17/918,093 | Osteoblasts Differentiated from Mesenchymal Stem Cells and Composition for Treating Bone Disease Comprising Same | Oct 8, 2021 | Pending |
| 18/029,239 | Composition Including PLGF for Prevention or Treatment of Neuropsychologic Disease | Sep 29, 2021 | Abandoned |
| 18/029,234 | Sep 29, 2021 | No status recorded |